Prior Lenalidomide Resistance and the Impact of IMiD-free Interval in Patients Treated with Pomalidomide and Dexamethasone

Meletios A Dimopoulos; Μαρία Ρούσσου; Nikolaos Kanellias; Maria Gavriatopoulou; Magdalini Migkou; Ioannis Panagiotidis; Evangelos Eleutherakis‐Papaiakovou; Dimitrios C. Ziogas; Despina Fotiou; Stavroula Giannouli; Panagiotis Tsirigotis; Despoina Mparmparousi; Charis Matsouka; Sossana Delimpasi; Evangelos Terpos; Efstathios Kastritis

doi:10.1016/j.clml.2017.03.210

Related publications

Article2019

Impact of last lenalidomide dose, duration, and IMiD-free interval in patients with myeloma treated with pomalidomide/dexamethasone

Efstathios Kastritis, Μαρία Ρούσσου, Maria Gavriatopoulou, Nikolaos Kanellias, Magdalini Migkou, Evangelos Eleutherakis‐Papaiakovou, Dimitrios C. Ziogas, Despina Fotiou, Ioannis Ntanasis‐Stathopoulos, Ioanna Dialoupi, Stavroula Giannouli, Panagiotis Tsirigotis, Sossana Delimpasi, Despina Mparmparousi, Mairylin Spyropoulou-Vlachou, Aikaterini Xirokosta, Evangelos Terpos, Meletios A Dimopoulos

Article2016

Pomalidomide with Low Dose Dexamethasone Is Effective Irrespective of Primary or Secondary Resistance to Lenalidomide but the IMiD-Free Interval Is Important

Meletios A Dimopoulos, Μαρία Ρούσσου, Nikolaos Kanellias, Maria Gavriatopoulou, Magdalini Migkou, Ioannis Panagiotidis, Evangelos Eleutherakis‐Papaiakovou, Dimitriοs Ziogas, Despina Fotiou, Stavroula Giannouli, Panagiotis Tsirigotis, Christos Poziopoulos, Sossana Delimpasi, Despoina Mparmparoussi, Charis Matsouka, Kostas Konstantopoulos, Evangelos Terpos, Efstathios Kastritis

Article2020

Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse

Meletios A Dimopoulos, Katja Weisel, Philippe Moreau, Larry D. Anderson, Darrell White, Jesús F. San Miguel, Pieter Sonneveld, Monika Engelhardt, Matthew Jenner, Alessandro Corso, Jan Dürig, Michel Pavic, Morten Salomo, Eva Casal, Shankar Srinivasan, Xin Yu, Tuong Vi Nguyen, Tsvetan Biyukov, Teresa Peluso, Paul G. Richardson

Article2016

Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study

Philippe Moreau, D. Joshua, W-J Chng, Antonio Palumbo, Hartmut Goldschmidt, Roman Hájek, Thierry Façon, Heinz Ludwig, Luděk Pour, Rubén Niesvizky, Albert Oriol, Laura Rosiñol, Aleksandr Suvorov, Gianluca Gaïdano, Tomáš Pika, Katja Weisel, Veselina Goranova‐Marinova, H H Gillenwater, Nehal Mohamed, Sanjay Aggarwal, Shibao Feng, Meletios A Dimopoulos

Article2010

Effects of Lenalidomide and Dexamethasone Treatment Duration on Survival in Patients With Relapsed or Refractory Multiple Myeloma Treated With Lenalidomide and Dexamethasone

Jesús F. San Miguel, Meletios A Dimopoulos, Edward A. Stadtmauer, S. Vincent Rajkumar, David S. Siegel, M. L. Casadebaig Bravo, Marta Olesnyckyj, Robert Knight, Jerome B. Zeldis, Jean‐Luc Harousseau, Donna M. Weber